Who is sponsoring NCT04092309?

NCT04092309 is sponsored by University of Athens.

What drugs are being tested in NCT04092309?

Interventions in NCT04092309: ACE inhibitor, Sacubitril-Valsartan.

What condition does NCT04092309 study?

NCT04092309 studies Hematopoietic Stem Cell Transplantation, Cardiotoxicity.

Is NCT04092309 still recruiting?

NCT04092309 is currently status unknown. Last updated 3 April 2020.

Last reviewed 2020-04-03 · How we verify

NCT04092309

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation

Status unknown NA Last updated 3 April 2020

What this trial tests

NA trial testing ACE inhibitor, Sacubitril-Valsartan in Hematopoietic Stem Cell Transplantation in 90 participants. Status unknown.

Timeline

20 September 2019

Primary endpoint
1 September 2020

1 September 2021

Quick facts

Lead sponsor	University of Athens
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	90
Start date	20 September 2019
Primary completion	1 September 2020
Estimated completion	1 September 2021
Sites	1 location across Greece

Drugs / interventions tested

ACE inhibitor, Sacubitril-Valsartan — full drug profile →

Conditions studied

Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →
Cardiotoxicity — all drugs for Cardiotoxicity →

Sponsor

University of Athens

Who can join

18 and older, any sex, with Hematopoietic Stem Cell Transplantation or Cardiotoxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the present study is to investigate the effect of ACE inhibitors and the sacubitril-valsartan complex in bone marrow transplant patients by assessing cardiovascular and endothelial parameters in order to search for a potent protective role.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: <i>JACC: CardioOncology</i> State-of-the-Art Review.
Omland T, Heck SL, Gulati G. · · 2022 · cited 113× · PMID 35492815 · DOI 10.1016/j.jaccao.2022.01.101
Management of Cardiac Toxicity Induced by Chemotherapy.
Trapani D, Zagami P, Nicolò E, Pravettoni G, et al · · 2020 · cited 31× · PMID 32906611 · DOI 10.3390/jcm9092885
The role of the renin-angiotensin system inhibitors in malignancy: a review.
Yang J, Yang X, Gao L, Zhang J, et al · · 2021 · cited 21× · PMID 33791161
Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer.
Altena R, Hubbert L, Kiani NA, Wengström Y, et al · · 2021 · cited 6× · PMID 34049593 · DOI 10.1186/s40959-021-00105-y
Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial.
Katogiannis K, Ikonomidis I, Farmakis D, Thymis J, et al · · 2025 · cited 4× · PMID 39983618 · DOI 10.1016/j.jacadv.2025.101628

Verify or expand the search:

Other recruiting trials for Hematopoietic Stem Cell Transplantation

Currently open trials in the same condition.

NCT07400328 — Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients · Phase 2 · recruiting
NCT07349498 — Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT06904053 — Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopo · recruiting
NCT06708507 — Tissue-resident Immune Cell Subsets in aGVHD · recruiting

Other University of Athens trials

Trials by the same sponsor.

NCT07469943 — The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness a · recruiting
NCT07254819 — Cotinus Coggygria Mouthwash and Halitosis and Oral Hygiene in Orthodontic Patients · NA · completed
NCT07069010 — Burnout Syndrome in the Intensive Care Unit Before and During a Palliative Care Trial · recruiting
NCT06766097 — Chios Mastic Toothpaste and Halitosis and Oral Hygiene in Orthodontic Patients · NA · not yet recruiting
NCT06885970 — The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04092309 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Athens
Last refreshed: 3 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04092309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing